Cargando…

Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status

BACKGROUND/AIMS: Antiviral therapy (AVT) reduces the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB). This multicenter retrospective study investigated the effects of AVT and hepatitis B virus (HBV)-related factors on the risk of HCC development in a coh...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mi Na, Hwang, Seong Gyu, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Han, Kwang-Hyub, Kim, Seung Up, Ahn, Sang Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430437/
https://www.ncbi.nlm.nih.gov/pubmed/30602075
http://dx.doi.org/10.5009/gnl18204
_version_ 1783405773920927744
author Kim, Mi Na
Hwang, Seong Gyu
Kim, Beom Kyung
Park, Jun Yong
Kim, Do Young
Han, Kwang-Hyub
Kim, Seung Up
Ahn, Sang Hoon
author_facet Kim, Mi Na
Hwang, Seong Gyu
Kim, Beom Kyung
Park, Jun Yong
Kim, Do Young
Han, Kwang-Hyub
Kim, Seung Up
Ahn, Sang Hoon
author_sort Kim, Mi Na
collection PubMed
description BACKGROUND/AIMS: Antiviral therapy (AVT) reduces the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB). This multicenter retrospective study investigated the effects of AVT and hepatitis B virus (HBV)-related factors on the risk of HCC development in a cohort with heterogeneous HBV status. METHODS: A total of 1,843 patients with CHB from two institutions were included in this study. Ultrasound and laboratory tests, including the α-fetoprotein test, were conducted regularly to detect HCC development. RESULTS: The mean age of our study population (1,063 men and 780 women) was 49.4 years. Cirrhosis was identified in 617 patients (33.5%). During follow-up (median, 42.5 months), 81 patients developed HCC (1.39% per person-year). A total of 645 patients (35.0%) received ongoing AVT at enrollment. Ongoing AVT was not significantly associated with the risk of HCC development (all p>0.05). HBV-related variables (HBV DNA level, hepatitis B e antigen status, and alanine aminotransferase level) were also not significantly associated with the risk of HCC development (all p>0.05). In contrast, cirrhosis was significantly associated with the risk of HCC development, regardless of adjustment (adjusted hazard ratio=4.098 to 7.020; all p<0.05). Cirrhosis significantly predicted the risk of HCC development in subgroups with and without ongoing AVT at enrollment, regardless of adjustment. CONCLUSIONS: Our study showed that cirrhosis, not AVT and HBV-related variables, was associated with HCC development in a cohort of patients with heterogeneous HBV status. Our results may help clinicians apply individualized surveillance strategies according to fibrotic status in patients with CHB.
format Online
Article
Text
id pubmed-6430437
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Editorial Office of Gut and Liver
record_format MEDLINE/PubMed
spelling pubmed-64304372019-04-01 Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status Kim, Mi Na Hwang, Seong Gyu Kim, Beom Kyung Park, Jun Yong Kim, Do Young Han, Kwang-Hyub Kim, Seung Up Ahn, Sang Hoon Gut Liver Original Article BACKGROUND/AIMS: Antiviral therapy (AVT) reduces the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB). This multicenter retrospective study investigated the effects of AVT and hepatitis B virus (HBV)-related factors on the risk of HCC development in a cohort with heterogeneous HBV status. METHODS: A total of 1,843 patients with CHB from two institutions were included in this study. Ultrasound and laboratory tests, including the α-fetoprotein test, were conducted regularly to detect HCC development. RESULTS: The mean age of our study population (1,063 men and 780 women) was 49.4 years. Cirrhosis was identified in 617 patients (33.5%). During follow-up (median, 42.5 months), 81 patients developed HCC (1.39% per person-year). A total of 645 patients (35.0%) received ongoing AVT at enrollment. Ongoing AVT was not significantly associated with the risk of HCC development (all p>0.05). HBV-related variables (HBV DNA level, hepatitis B e antigen status, and alanine aminotransferase level) were also not significantly associated with the risk of HCC development (all p>0.05). In contrast, cirrhosis was significantly associated with the risk of HCC development, regardless of adjustment (adjusted hazard ratio=4.098 to 7.020; all p<0.05). Cirrhosis significantly predicted the risk of HCC development in subgroups with and without ongoing AVT at enrollment, regardless of adjustment. CONCLUSIONS: Our study showed that cirrhosis, not AVT and HBV-related variables, was associated with HCC development in a cohort of patients with heterogeneous HBV status. Our results may help clinicians apply individualized surveillance strategies according to fibrotic status in patients with CHB. Editorial Office of Gut and Liver 2019-03 2019-02-12 /pmc/articles/PMC6430437/ /pubmed/30602075 http://dx.doi.org/10.5009/gnl18204 Text en Copyright © 2019 by The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Mi Na
Hwang, Seong Gyu
Kim, Beom Kyung
Park, Jun Yong
Kim, Do Young
Han, Kwang-Hyub
Kim, Seung Up
Ahn, Sang Hoon
Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status
title Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status
title_full Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status
title_fullStr Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status
title_full_unstemmed Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status
title_short Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status
title_sort liver cirrhosis, not antiviral therapy, predicts clinical outcome in cohorts with heterogeneous hepatitis b viral status
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430437/
https://www.ncbi.nlm.nih.gov/pubmed/30602075
http://dx.doi.org/10.5009/gnl18204
work_keys_str_mv AT kimmina livercirrhosisnotantiviraltherapypredictsclinicaloutcomeincohortswithheterogeneoushepatitisbviralstatus
AT hwangseonggyu livercirrhosisnotantiviraltherapypredictsclinicaloutcomeincohortswithheterogeneoushepatitisbviralstatus
AT kimbeomkyung livercirrhosisnotantiviraltherapypredictsclinicaloutcomeincohortswithheterogeneoushepatitisbviralstatus
AT parkjunyong livercirrhosisnotantiviraltherapypredictsclinicaloutcomeincohortswithheterogeneoushepatitisbviralstatus
AT kimdoyoung livercirrhosisnotantiviraltherapypredictsclinicaloutcomeincohortswithheterogeneoushepatitisbviralstatus
AT hankwanghyub livercirrhosisnotantiviraltherapypredictsclinicaloutcomeincohortswithheterogeneoushepatitisbviralstatus
AT kimseungup livercirrhosisnotantiviraltherapypredictsclinicaloutcomeincohortswithheterogeneoushepatitisbviralstatus
AT ahnsanghoon livercirrhosisnotantiviraltherapypredictsclinicaloutcomeincohortswithheterogeneoushepatitisbviralstatus